Headlines about Aratana Therapeutics (NASDAQ:PETX) have trended positive recently, according to Accern Sentiment. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aratana Therapeutics earned a media sentiment score of 0.29 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 47.8832671499903 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern’s scoring:
- Aratana Therapeutics Q4 Earnings Preview (finance.yahoo.com)
- Aratana Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results (finance.yahoo.com)
- Earnings surprise are on radar for Aratana Therapeutics Inc NASDAQ:PETX And Aralez Pharmaceuticals Inc NASDAQ:ARLZ ? (stockmarketdaily.co)
- When Can We Expect A Profit From Aratana Therapeutics Inc (NASDAQ:PETX)? (finance.yahoo.com)
- Aratana Therapeutics (PETX) Upgraded by CL King to Buy (americanbankingnews.com)
Aratana Therapeutics (NASDAQ PETX) traded down $0.58 on Wednesday, reaching $3.85. The company’s stock had a trading volume of 1,150,665 shares, compared to its average volume of 414,223. The company has a current ratio of 3.42, a quick ratio of 3.08 and a debt-to-equity ratio of 0.26. The stock has a market cap of $190.06, a P/E ratio of -2.66 and a beta of 3.13. Aratana Therapeutics has a 12-month low of $3.71 and a 12-month high of $7.67.
In other news, CEO Peter Steven St sold 19,367 shares of the stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $4.77, for a total transaction of $92,380.59. Following the completion of the transaction, the chief executive officer now directly owns 672,259 shares of the company’s stock, valued at approximately $3,206,675.43. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Craig A. Tooman sold 30,000 shares of the stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $5.27, for a total value of $158,100.00. Following the transaction, the insider now directly owns 75,024 shares of the company’s stock, valued at $395,376.48. The disclosure for this sale can be found here. 5.20% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Favorable News Coverage Somewhat Unlikely to Impact Aratana Therapeutics (PETX) Share Price” was originally reported by BBNS and is owned by of BBNS. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://baseballnewssource.com/2018/03/14/favorable-news-coverage-somewhat-unlikely-to-impact-aratana-therapeutics-petx-share-price/2029656.html.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.